Early Gynecologic Cancers

Serum Biomarkers for Early Detection of Gynecologic Cancers

Ovarian, endometrial, and cervical cancers are three of the most common malignancies of the female reproductive organs. CA 125, historically the most reliable serum marker for ovarian cancer, is elevated in 50% of early-stage ovarian tumors. For endometrial cancers, there are no established serum markers. SCC, which is the best studied serum marker for squamous cell carcinomas, has been unrelia...

Laparoscopy for Gynecologic Cancers

Palliative Care in Gynecologic Cancers

Gynecologic cancers constitute a significant part of cancer load, especially in developing countries, and may be an important reason for mortality and morbidity for women in these countries. Procedures in diagnosis and treatment for gynecologic cancers might remain insufficient, and disorders related to symptoms may negatively influence the quality of life of women and their families. In this r...

Neoadjuvant Chemotherapy in Gynecologic Cancers

Neoadjuvant chemotherapy is introduced in many gynecologic cancers such as cervical and ovarian cancer. The aim of using neoadjuvant chemotherapy is to reduce the tumor size prior to the principle treatment, either radiation or surgery. The benefit of reducing tumor size can increase the operability and decrease the morbidity in many types of gynecologic cancers. Besides this, neoadjuvant chemo...

Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers

HEALTH ISSUE: In Canada, cancers of the endometrium, ovaries, vulva, vagina, placenta and adnexa account for 11% of all malignant neoplasms in women and 81% of all genital cancers. Although the incidence and mortality from vulvar and vaginal cancers are very low, endometrium and ovarian cancer are important public health problems. KEY FINDINGS: In Canada, there has been no appreciable improveme...